A Study of YL201 in Patients With Advanced Solid Tumors (NCT05434234)
A Phase 1A/1B, Multicenter, Nonrandomized, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL201 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohorts of patients with advanced solid tumors unresponsive to currently available therapies or for whom no standard therapy is available. Part 2 will include patients with selected advanced solid tumor types enrolled at the MTD/RED(s), to better define the safety profile and evaluate the efficacy of YL201.
Who can join: Review the eligibility criteria below.
Location: 002 — Fair Oaks, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (45 Sites)
Showing the first 25 of 45 sites.
- 002 — Fair Oaks, California
- 001 — La Jolla, California
- 003 — Lone Tree, Colorado
- 004 — Washington D.C., District of Columbia
- 005 — Boston, Massachusetts
- 006 — Ann Arbor, Michigan
- 007 — Detroit, Michigan
- 008 — St Louis, Missouri
- 009 — Santa Fe, New Mexico
- 010 — New York, New York
- 011 — Chapel Hill, North Carolina
- 012 — Nashville, Tennessee
- 014 — Houston, Texas
- 015 — Irving, Texas
- 013 — San Antonio, Texas
- 016 — Tyler, Texas
- 017 — Fairfax, Virginia
- 018 — Spokane, Washington
- 019 — Tacoma, Washington
- 020 — Edmonton, Alberta
- 021 — Kelowna, British Columbia
- 022 — Brampton, Ontario
- 023 — Toronto, Ontario
- 024 — Guangzhou, Guangdong
- 025 — Zhengzhou, Henan
📞 Contact the Study Coordinator
Phone: (617) 240-8494
Email: info@medilinkthera.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumor
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
- A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
- QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
- A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
- First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
- A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas
Explore by condition: All Advanced Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.